HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...
Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback